工商銀行(01398.HK)擬派發境外優先股股息
格隆匯10月25日丨工商銀行(01398.HK)公告,中國工商銀行股份有限公司在2014年9月19日舉行的2014年第二次臨時股東大會審議通過了《關於中國工商銀行股份有限公司境外發行優先股股票方案的議案》,授權董事會根據發行方案的約定,決定並辦理向境外優先股股東支付股息事宜。次境外優先股股息派發方案已經行2019年10月25日召開的董事會會議審議通過。
股息支付日:2019年12月10日。派發境外優先股股息為1.96億美元、4000萬歐元和8億元人民幣(含税)。按照有關法律規定,在派發境外優先股股息時,需按10%的税率代扣代繳所得税,按照境外優先股條款和條件有關規定,相關税費由行承擔。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.